| Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine M Drozdzik, C Gröer, J Penski, J Lapczuk, M Ostrowski, Y Lai, B Prasad, ... Molecular pharmaceutics 11 (10), 3547-3555, 2014 | 273 | 2014 |
| Strategies for characterizing sildenafil, vardenafil, tadalafil and their analogues in herbal dietary supplements, and detecting counterfeit products containing these drugs S Singh, B Prasad, AA Savaliya, RP Shah, VM Gohil, A Kaur TrAC Trends in Analytical Chemistry 28 (1), 13-28, 2009 | 209 | 2009 |
| Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem … B Prasad, R Evers, A Gupta, CECA Hop, L Salphati, S Shukla, ... Drug Metabolism and Disposition 42 (1), 78-88, 2014 | 203 | 2014 |
| Interspecies variability in expression of hepatobiliary transporters across human, dog, monkey, and rat as determined by quantitative proteomics L Wang, B Prasad, L Salphati, X Chu, A Gupta, CECA Hop, R Evers, ... Drug Metabolism and Disposition 43 (3), 367-374, 2015 | 193 | 2015 |
| Interindividual variability in cytochrome P450–mediated drug metabolism TS Tracy, AS Chaudhry, B Prasad, KE Thummel, EG Schuetz, X Zhong, ... Drug Metabolism and Disposition 44 (3), 343-351, 2016 | 157 | 2016 |
| Metabolite identification by liquid chromatography-mass spectrometry B Prasad, A Garg, H Takwani, S Singh TrAC Trends in Analytical Chemistry 30 (2), 360-387, 2011 | 144 | 2011 |
| Abundance of drug transporters in the human kidney cortex as quantified by quantitative targeted proteomics B Prasad, K Johnson, S Billington, C Lee, GW Chung, CDA Brown, ... Drug Metabolism and Disposition 44 (12), 1920-1924, 2016 | 142 | 2016 |
| Ontogeny of hepatic drug transporters as quantified by LC‐MS/MS proteomics B Prasad, A Gaedigk, M Vrana, R Gaedigk, JS Leeder, L Salphati, X Chu, ... Clinical Pharmacology & Therapeutics 100 (4), 362-370, 2016 | 140 | 2016 |
| Ten years’ experience with the CYP2D6 activity score: a perspective on future investigations to improve clinical predictions for precision therapeutics A Gaedigk, JC Dinh, H Jeong, B Prasad, JS Leeder Journal of personalized medicine 8 (2), 15, 2018 | 137 | 2018 |
| Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype B Prasad, Y Lai, Y Lin, JD Unadkat Journal of pharmaceutical sciences 102 (3), 787-793, 2013 | 122 | 2013 |
| Optimized approaches for quantification of drug transporters in tissues and cells by MRM proteomics B Prasad, JD Unadkat The AAPS journal 16, 634-648, 2014 | 116 | 2014 |
| Cytochrome P450-dependent catabolism of vitamin K: ω-hydroxylation catalyzed by human CYP4F2 and CYP4F11 KZ Edson, B Prasad, JD Unadkat, Y Suhara, T Okano, FP Guengerich, ... Biochemistry 52 (46), 8276-8285, 2013 | 104 | 2013 |
| Age‐and genotype‐dependent variability in the protein abundance and activity of six major uridine diphosphate‐glucuronosyltransferases in human liver DK Bhatt, A Mehrotra, A Gaedigk, R Chapa, A Basit, H Zhang, ... Clinical Pharmacology & Therapeutics 105 (1), 131-141, 2019 | 102 | 2019 |
| Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry AK Deo, B Prasad, L Balogh, Y Lai, JD Unadkat Drug Metabolism and Disposition 40 (5), 852-855, 2012 | 94 | 2012 |
| Toward a consensus on applying quantitative liquid chromatography‐tandem mass spectrometry proteomics in translational pharmacology research: a white paper B Prasad, B Achour, P Artursson, CECA Hop, Y Lai, PC Smith, J Barber, ... Clinical Pharmacology & Therapeutics 106 (3), 525-543, 2019 | 91 | 2019 |
| Age-dependent absolute abundance of hepatic carboxylesterases (CES1 and CES2) by LC-MS/MS proteomics: application to PBPK modeling of oseltamivir in vivo pharmacokinetics in … M Boberg, M Vrana, A Mehrotra, RE Pearce, A Gaedigk, DK Bhatt, ... Drug Metabolism and Disposition 45 (2), 216-223, 2017 | 82 | 2017 |
| Abundance of phase 1 and 2 drug-metabolizing enzymes in alcoholic and hepatitis C cirrhotic livers: a quantitative targeted proteomics study B Prasad, DK Bhatt, K Johnson, R Chapa, X Chu, L Salphati, G Xiao, ... Drug Metabolism and Disposition 46 (7), 943-952, 2018 | 79 | 2018 |
| Screening of Indian aphrodisiac ayurvedic/herbal healthcare products for adulteration with sildenafil, tadalafil and/or vardenafil using LC/PDA and extracted ion LC–MS/TOF AA Savaliya, RP Shah, B Prasad, S Singh Journal of pharmaceutical and biomedical analysis 52 (3), 406-409, 2010 | 78 | 2010 |
| Developmental regulation of drug-processing genes in livers of germ-free mice FP Selwyn, SL Cheng, TK Bammler, B Prasad, M Vrana, C Klaassen, ... Toxicological Sciences 147 (1), 84-103, 2015 | 76 | 2015 |
| Interindividual and regional variability in drug transporter abundance at the human blood–brain barrier measured by quantitative targeted proteomics S Billington, L Salphati, CECA Hop, X Chu, R Evers, D Burdette, ... Clinical Pharmacology & Therapeutics 106 (1), 228-237, 2019 | 74 | 2019 |
Jashvant UnadkatVerified email at uw.edu
